Search
Sign Up
Home
Team
Pipeline
Back
Sr89/Metastron
QBM-001
Uttroside-B
MAN-01
Investors
Back
Presentations
Stock Info
Filings
Media
News
Back
News 2024
News 2023
News 2022
News 2021
News 2020
News 2019
News 2018
News 2017
News 2016
Contact
Video & Social Media
Watch us in interviews. Follow us.
2020 News
List of articles in category 2020 News
Title
Created Date
Q BioMed Updates Shareholders at Year End
Dec 29, 2020
Q BioMed Technology Partner Mannin Research Inc. Announced as Member of Canadian National COVID-19 Consortium
Dec 21, 2020
Q BioMed's Strontium89 Advertisement "Unfinished Business" Selected for Prestigious Ads of the World's Best Creative Campaigns
Nov 20, 2020
Q BioMed’s Uttroside-B Receives U.S. Patent in Treatment of Liver Cancer
Nov 16, 2020
Q BioMed Announces Strontium89 Initial Uptake and Momentum in US and Europe
Sep 15, 2020
Q BioMed Announces Initiation of GMP Production of Novel COVID-19 Therapeutic for Clinical Trial Program
Aug 26, 2020
Q BioMed Announces Strontium89 will be available as of September 2020 through Named Patient Program for Bone Metastases Pain Palliation in EU and Rest of World
Aug 11, 2020
Q BioMed To Scale Up Production Of Uttroside-B, A Novel Chemotherapeutic For Liver Cancer, In Preparation For IND Filing
Jul 22, 2020
Q BioMed Announces Global Distribution Partnership with Caligor Coghlan Pharma Services for its Non-Opioid Cancer Palliation Drug
Jul 08, 2020
Q BioMed Updates Shareholders
Jun 30, 2020
Q BioMed Launches New Website Strontium89.com and Digital Marketing Campaign for Strontium89 (Strontium Chloride Sr-89 Injection, USP) Non-Opioid Treatment for Metastatic Bone Pain
May 15, 2020
Denis Corin, CEO, of Q BioMed Inc. Provides Key Updates and Outlook in a New Audio Interview with SmallCapVoice.com
Apr 30, 2020
Q BioMed Inc. Discusses The Commercialization of Its FDA Approved Metastatic Bone Pain Drug with The Stock Day Podcast
Apr 27, 2020
Q BioMed Initiates Rapid Development of Novel COVID-19 Therapeutics
Apr 22, 2020
Q BioMed Enters into a Financial Restructuring of Approximately $7,800,000 Consisting of $4,000,000 New Cash and a minimum of $3,800,000 of Debt Conversion
Apr 07, 2020
Q BioMed Adds to Leadership Team with Global Head of Regulatory Affairs
Mar 31, 2020
Q BioMed Expands Leadership Team with Chief Commercial Officer
Mar 30, 2020
Q BioMed Treats its First Patient in Commercial Setting Following Product Launch
Mar 12, 2020
Q BioMed Launches Non-Opioid Treatment for Metastatic Bone Pain
Feb 13, 2020
Q BioMed Partner Mannin Research Developing Potential Treatment for Patients Infected with Coronavirus and other Infectious Diseases
Feb 04, 2020
Q BioMed Provides a Shareholder Update Ahead of the Commercial Launch of its First Drug
Jan 07, 2020